Special Issue

Applications of Nanotechnology for Melanoma Treatment and Diagnosis

Message from the Guest Editors

Melanoma is an aggressive form of skin cancer with increasing global incidence, which constitutes an alarming public health problem. Despite the favorable prognoses attributed to patients diagnosed at early stages of the disease, those in advanced stages entail high rates of mortality and morbidity, with concerning profiles of pharmacoresistance. In this Special Issue, we invite researchers to submit their work on strategies to boost and improve the treatment and/or diagnosis of melanoma, using emerging nanotechnological approaches. Topics include, but are not limited to new incorporated/encapsulated synthetic molecules, natural-derived compounds, photosensitizing agents, immunotherapy, targeted therapy, metal-based complexes, drug- or protein-conjugates, novel cellular delivery approaches, lipid-based systems, polymeric and metallic nanoparticles, preclinical research, etc. We hope this Special Issue will provide new insights into understanding the progression of melanoma, developing more effective methods for diagnosis and promoting novel therapeutic strategies for the treatment of this disease.

Guest Editors

Dr. Mariana Matias

Research Institute for Medicines, iMed.ULisboa, Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal

Dr. Maria Manuela Gaspar

iMed.ULisboa, Research Institute for Medicines, Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal

Deadline for manuscript submissions

closed (25 November 2023)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/138017

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

